Document:

Exhibit 10.19

    

      Exhibit
        10.19

      

      
        	
                Notice
                  of Grant of Stock Option 

                Director

              	
                Eclipsys
                  Corporation

                ID:
                  65-0632092

              
	
                «Name»

                «StreetAddress»

                «CityStateZip»

              	
                Option
                  Number: «OptionNumber»

                Plan: 2005
                  Stock Incentive Plan

              
	
                 

                Effective
                  ___________ (the “Grant
                  Date”),
                  you have been granted a non-statutory option to buy «TotalShares»
                  shares of common stock of Eclipsys Corporation (the "Company")
                  at an exercise price of $_________ per share. This option vests
                  and
                  becomes exercisable (i) with respect to 20% of the underlying shares
                  on
                  the first day of the calendar month immediately following the first
                  anniversary of the Grant Date (the “First Vesting Date”); and (ii) with
                  respect to the remaining 80% of the underlying shares in 48 equal
                  consecutive monthly installments on the first day of each calendar
                  month
                  following the First Vesting Date, provided that vesting will not
                  occur if
                  you are not employed with the Company (as defined in the Plan)
                  on the
                  scheduled vesting date. 

                 

                The
                  option is granted under and governed by the terms and conditions
                  of this
                  notice, the Company's 2005 Stock Incentive Plan (the “Plan”),
                  and any other applicable written agreement between you and the
                  Company. By
                  your acceptance of this option, and also by its exercise, you agree
                  to
                  such terms and conditions and confirm that your receipt and exercise
                  of
                  this option is voluntary. 

                 

                If
                  you cease to be a member of the Company’s Board of Directors in connection
                  with a Change in Control Event (as defined in the Plan) for any
                  reason
                  other than voluntary resignation from the Board, which Board will
                  continue
                  in place following the Change in Control Event, then upon such
                  a cessation
                  of your directorship the option will vest in full. 

                 

                Except
                  as otherwise provided in this Notice or the Plan or a separate
                  written
                  agreement between you and the Company signed by an executive officer
                  of
                  the Company, (i) termination of your service as a member of the
                  Company’s
                  Board of Directors for any reason (unless you are then or then
                  becoming an
                  employee of the Company as defined in the Plan) will result in
                  cessation
                  of vesting and lapse of the option to the extent not yet vested
                  at the
                  time of termination; and (ii) vested options may be exercised only
                  for a
                  period of 365 days following termination of your service as a member
                  of
                  the Company’s Board of Directors (or, if later, 365 days following
                  termination of your employment). The option expires, to the extent
                  not
                  earlier terminated or exercised, on the tenth anniversary of the
                  Grant
                  Date or such earlier date as the Plan provides.

                 

                Unless
                  otherwise permitted by the Company’s Board of Directors, you must pay the
                  exercise price and meet any tax obligations in cash.

              
	
                 

                The
                  Prospectus for the Plan, the Plan document, the Company’s Annual Report on
                  Form 10-K, and other filings made by the Company with the Securities
                  and
                  Exchange Commission are available for your review on the Company’s
                  internal employee web site. You may also obtain paper copies of
                  these
                  documents upon request to the Company’s HR department.

                 

                No
                  representations or promises are made regarding the duration of
                  your
                  service, vesting of the option, the value of the Company's stock
                  or this
                  option, or the Company's prospects. The Company provides no advice
                  regarding tax consequences or your handling of the option; you
                  agree to
                  rely only upon your own personal advisors.

              
	
                 

                ECLIPSYS
                  CORPORATION

                 

                By:      

                Name

                TitleQuickLinks
 -- Click here to rapidly navigate through this document

Exhibit 10.a.1  

 
 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM    
    

        We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-92229) pertaining to the 1993
Stock Option Plan and the 1996 Employee Stock Purchase Plan and in the Registration Statement (Form S-8 No. 333-138697) pertaining to the 2006 Stock Option Plan
of Biovail Corporation, of our report dated March 19, 2007, except for note 3, as to which the date is May 22, 2007, with respect to the consolidated financial statements
and schedule of Biovail Corporation, and our report dated March 19, 2007, except for the effects of the material weaknesses described in the sixth paragraph, as to which the date is
May 22, 2007, with respect to Biovail Corporation management's assessment of the effectiveness of internal control over financial reporting, and the effectiveness of internal control over
financial reporting of Biovail Corporation, included in the amended Annual Report (Form 20-F/A) for the year ended December 31, 2006. 

	Toronto, Canada	 	/s/ ERNST & YOUNG LLP
	May 22, 2007	 	Chartered Accountants

Licensed Public Accountants

QuickLinks

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRMQuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 4.8    
    

NOVACARDIA, INC.

AMENDMENT No. 1 TO

AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT  

        THIS AMENDMENT NO. 1 TO AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT (the
"Amendment") is made as of March 21, 2007, by and among NOVACARDIA, INC., a Delaware
corporation (the "Company"), the holders of Series A Preferred Stock of the Company ("Series A
Preferred") as listed on Exhibit A to the Investors' Rights Agreement (as defined below) (the "Series A Holders"),
the holders of the Series B Preferred Stock of the Company ("Series B Preferred") as listed on Exhibit B to the Investors' Rights
Agreement (the "Series B Holders"), Lighthouse (as defined in the Investors' Rights Agreement), TriplePoint Capital
("TriplePoint") and the Follow-On Series B Holders (as defined below) (the Series A Holders, the Series B Holders and
the Follow-On Series B Holders are collectively referred to herein as the "Investors" and each individually referred to herein as an
"Investor"). 

RECITALS  

        A.    On September 21, 2006, the Company and the Series B Holders entered into a Series B Preferred Stock
Purchase Agreement (the "Series B Purchase Agreement") pursuant to which the Company sold to the Series B Holders and the Series B
Holders purchased from the Company, shares of the Series B Preferred. In connection therewith, the Company, the Series A Holders, Lighthouse and the Series B Holders entered into
the Amended and Restated Investors' Rights Agreement dated September 21, 2006 (the "Investors' Rights Agreement"). 

        B.    The Company, certain of the Series B Holders and an additional purchaser have entered into a Follow-On
Series B Preferred Stock Purchase Agreement (the "Follow-On Series B Purchase Agreement") of even date herewith, pursuant to
which the Company desires to sell to the Purchasers, as defined in the Follow-On Series B Purchase Agreement (referred to herein as the
"Follow-On Series B Holders"), and the Follow-On Series B Holders desire to purchase from the Company, additional
shares of Series B Preferred. A condition to the Follow-On Series B Holders' obligations under the Follow-On Series B Purchase Agreement, is that the
Company obtain the requisite consent of the parties to the Investors' Rights Agreement to amend the Investors' Rights Agreement as set forth in this Amendment. 

        C.    Following the closing contemplated by the Follow-On Series B Purchase Agreement, the Company also
intends to enter into a Loan and Security Agreement with TriplePoint in connection with a debt facility from TriplePoint in an aggregate principal amount of up to $20,000,000 (the
"TriplePoint Debt Facility"). In connection with the TriplePoint Debt Facility, the Company will issue one or more warrants (the
"TriplePoint Warrants") to TriplePoint to acquire shares of Series B Preferred. In connection with the TriplePoint Debt Facility, the Company has
agreed to grant to TriplePoint registration rights with respect to the shares of the Company's common stock (the "Common Stock") issuable upon exercise
of the TriplePoint Warrants (or issuable upon conversion of the Series B Preferred issuable upon exercise thereof) (the "Exercise Shares"), and
the requisite parties to the Investors' Rights Agreement desire to amend the Investors' Rights Agreement to add TriplePoint as a "Holder" thereunder and to include the Exercise Shares as "Registrable
Securities" thereunder. In connection with the TriplePoint Debt Facility, the Company also will be required to grant to TriplePoint the right to participate in the Company's next private preferred
stock financing (excluding the financing contemplated by the Follow-On Series B Purchase Agreement) that occurs prior to an initial public offering of the Company's Common Stock by
purchasing up to five percent (5%) of the aggregate shares of preferred stock sold in such financing, as more fully set forth in the TriplePoint Debt Facility. 

        D.    Any term of the Investors' Rights Agreement may be amended or waived with the written consent of the Company and the
holders of at least sixty-six and two-thirds percent (662/3%) of the 

 

Registrable
Securities then outstanding (as defined in the Investors' Rights Agreement) and the Company and the undersigned holders of at least sixty-six and two-thirds percent
(662/3%) of the outstanding Registrable Securities desire to amend the Investors' Rights Agreement as provided herein. 

        NOW THEREFORE, in consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 

AGREEMENT  

        1.     By this Amendment, all references to "Investors" in the Investors' Rights Agreement, as amended hereby, shall include the
Follow-On Series B Holders and Exhibit B to the Investors' Rights Agreement shall be amended hereby to include each of the Follow-On Series B Holders to
the extent not already listed therein. 

        2.     The definition of "Holder" set forth in Section 1.1(c) of the Investors' Rights Agreement shall be deleted and
replaced in its entirety with the following definition: 

        "(c)
The term "Holder" means any person owning or having the right to acquire Registrable Securities or any assignee thereof in accordance
with Section 1.12 of this Agreement, and shall include, without limitation, Lighthouse and TriplePoint;" 

        3.     Subsection (i) of the definition of "Registrable Securities" set forth in Section 1.1(g) of the Investors'
Rights Agreement shall be deleted and replaced in its entirety with the following: 

        "(i) the
shares of Common Stock issuable or issued upon conversion of the Preferred Stock (including without limitation Preferred Stock issued to Lighthouse and TriplePoint or
shares of Common Stock otherwise issued upon exercise of the warrants held by Lighthouse and TriplePoint), other than shares for which registration rights have terminated pursuant to
Section 1.15 hereof," 

        4.     The definition of "Restated Certificate" set forth in Section 1.1(i) of the Investors' Rights Agreement
shall be deleted and replaced in its entirety with the following definition: 

        "(i)
The term "Restated Certificate" shall mean the Company's Third Amended and Restated Certificate of Incorporation, as such may be
amended from time to time;" 

        5.     The word "and" at the end of Section 1.1(j) of the Investors' Rights Agreement is hereby deleted. 

        6.     The period at the end of Section 1.1(k) of the Investors' Rights Agreement is hereby deleted. 

        7.     The following new definitions are added as Sections 1.1(l) and 1.1(m) of the Investors' Rights Agreement, directly below
Section 1.1(k): 

        "(l)
The term "TriplePoint" means TriplePoint Capital; and 

        (m)
The term "TriplePoint Debt Facility" means that certain Loan and Security Agreement between the Company and TriplePoint entered into
in March 2007, as such may be amended from time to time." 

        8.     A new Section 2.3(e) is hereby added to the Investors' Rights Agreement to read as follows: 

        "(e)
Notwithstanding the foregoing provisions of this Section 2.3, each of the Investors acknowledges and agrees that (i) the Company intends to enter into the TriplePoint
Debt Facility, which includes a provision in Section 19 thereof whereby TriplePoint has the right to purchase up to five percent (5%) of the aggregate shares of preferred stock issued in
connection with the Company's next private preferred stock financing (excluding the shares of Series B Preferred sold 

2

 

pursuant
to the Follow-On Series B Purchase Agreement (as defined below)) that occurs prior to the initial public offering of the Company's Common Stock, as more fully described in
the TriplePoint Debt Facility, (ii) the rights set forth in this Section 2.3 shall not conflict with and shall be subject to the participation rights of TriplePoint set forth in the
TriplePoint Debt Facility, and (iii) any shares of preferred stock issued to TriplePoint pursuant to such participation right shall not be subject to the right of first offer in this
Section 2.3." 

        9.     The first sentence in Section 2.4 of the Investors' Rights Agreement is hereby deleted in its entirety and replaced
with the following new first sentence: 

        "In
the event that the Company proposes to take an action or engage in a transaction that would reasonably be expected to result in the shares being purchased under the Series A
Purchase Agreement, the Series B Purchase Agreement or the Follow-On Series B Preferred Stock Purchase Agreement dated March 16, 2007 by and among the Company and the
purchasers named therein (the "Follow-On Series B Purchase Agreement") no longer being "qualified small
business stock" within the meaning of Section 1202(c) of the Internal Revenue Code of 1986, as amended (the
"Code"), the Company shall notify the Investors and consult in good faith to devise a mutually agreeable and reasonable alternative course of action or
transaction structure that would preserve such status." 

        10.   For purposes of the Investors' Rights Agreement, TriplePoint and any other holder of the TriplePoint Warrants and the
Series B Preferred issuable upon exercise thereof (or of the shares of Common Stock issuable upon conversion of such shares of Series B Preferred or otherwise issuable upon exercise of
such TriplePoint Warrants) shall be deemed to be the record holder or holders of the Registrable Securities issuable directly or indirectly upon exercise and/or conversion thereof. 

        11.   All notices and other communications under the Investors' Rights Agreement for TriplePoint shall be made to TriplePoint
at the address specified below and thereafter at such other address, notice of which is given in accordance with Section 3.5 of the Investors' Rights Agreement: 

TriplePoint
Capital

2420 San Hill Road

Suite 101

Menlo Park, California 94025

Attn: Sajal Srivastava, COO

Phone: (650) 854-2090

Fax: (650) 854-2094 

        12.   The restrictions on transfer and assignment set forth in Section 1.12 of the Investors' Rights Agreement shall not
apply to TriplePoint. 

[Signatures
Follow] 

3

        IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first written above. 

	 	 	COMPANY:
	

 	
 	
NOVACARDIA, INC., a Delaware corporation
	

 	
 	

By:	
 	

/s/ Randall E. Woods
 Randall E. Woods,

Chief Executive Officer
	

 	
 	
LIGHTHOUSE:
	

 	
 	
Lighthouse Capital Partners V, L.P.
	

 	
 	

By:	
 	

Lighthouse Management Partners V, L.L.C., its general partner
	

 	
 	

By:	
 	

	 	 	Name:	 	

	 	 	Title:	 	

	
[SIGNATURE PAGE TO AMENDMENT NO. 1 TO

AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT]

	 	 	INVESTORS:
	

 	
 	
SKYLINE VENTURE PARTNERS QUALIFIED PURCHASER FUND IV, L.P.
	

 	
 	

By:	
 	

Skyline Venture Management IV, LLC, its General Partner
	

 	
 	

By:	
 	

/s/ Yasunori Kaneko

	 	 	Name:	 	Yasunori Kaneko

	 	 	Its:	 	Managing Director

525 University Ave., Suite 520

Palo Alto, CA 94301
	

 	
 	
SKYLINE VENTURE PARTNERS III, L.P.
	

 	
 	

By:	
 	

Skyline Venture Management III, LLC, its General Partner
	

 	
 	

By:	
 	

/s/ Yasunori Kaneko

	 	 	Name:	 	Yasunori Kaneko

	 	 	Its:	 	Managing Director

525 University Ave., Suite 520

Palo Alto, CA 94301
	

 	
 	
SKYLINE VENTURE PARTNERS QUALIFIED PURCHASER FUND III, L.P.
	

 	
 	

By:	
 	

Skyline Venture Management III, LLC, its General Partner
	

 	
 	

By:	
 	

/s/ Yasunori Kaneko

	 	 	Name:	 	Yasunori Kaneko

	 	 	Its:	 	Managing Director

525 University Ave., Suite 520

Palo Alto, CA 94301
	
[SIGNATURE PAGE TO AMENDMENT NO. 1 TO

AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT]

	 	 	INTERWEST PARTNERS IX, LP
	

 	
 	

By:	
 	

InterWest Management Partners IX, LLC, its General Partner
	

 	
 	

By:	
 	

/s/ Nina Kjellson
 Nina Kjellson

Venture Member

2710 Sand Hill Rd.

Second Floor

Menlo Park, CA 94025
	

 	
 	
DOMAIN PARTNERS V, L.P.
	

 	
 	

By:	
 	

One Palmer Square Associates V, L.L.C., its General Partner
	

 	
 	

By:	
 	

/s/ Kathleen K. Schoemaker
 Kathleen K. Schoemaker

Managing Member

One Palmer Square, Suite 515

Princeton, New Jersey 08542
	

 	
 	
DP V ASSOCIATES, L.P.
	

 	
 	

By:	
 	

One Palmer Square Associates V, L.L.C., its General Partner
	

 	
 	

By:	
 	

/s/ Kathleen K. Schoemaker
 Kathleen K. Schoemaker

Managing Member

One Palmer Square, Suite 515

Princeton, New Jersey 08542
	
[SIGNATURE PAGE TO AMENDMENT NO. 1 TO

AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT]

	 	 	FORWARD VENTURES V, L.P.
	

 	
 	

By:	
 	

Forward V Associates, LLC, its General Partner
	

 	
 	

By:	
 	

/s/ Stuart Collinson
 Stuart Collinson

Key Voting Member

Forward Ventures V, L.P.

9393 Towne Centre Drive, Suite 200

San Diego, CA 92121
	

 	
 	
MONTREUX EQUITY PARTNERS III SBIC, L.P.
	

 	
 	

By:	
 	

Montreux Equity Management III, LLC, its General Partner
	

 	
 	

By:	
 	

/s/ Daniel K. Turner III
 Daniel K. Turner III

Managing Member

3000 Sand Hill Road, Suite 260

Menlo Park, CA 94025-7073
	
[SIGNATURE PAGE TO AMENDMENT NO. 1 TO

AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT]

	 	 	VERSANT VENTURE CAPITAL II, L.P.
	

 	
 	

By:	
 	

Versant Ventures II, L.L.C., its General Partner
	

 	
 	

By:	
 	

/s/ Camille Samuels Pearson
 Camille Samuels Pearson

Managing Director

3000 Sand Hill Road

Building 4, Suite 210

Menlo Park, CA 94025
	

 	
 	
VERSANT AFFILIATES FUND II-A, L.P.
	

 	
 	

By:	
 	

Versant Ventures II, L.L.C., its General Partner
	

 	
 	

By:	
 	

/s/ Camille Samuels Pearson
 Camille Samuels Pearson

Managing Director

3000 Sand Hill Road

Building 4, Suite 210

Menlo Park, CA 94025
	

 	
 	
VERSANT SIDE FUND II, L.P.
	

 	
 	

By:	
 	

Versant Ventures II, L.L.C., its General Partner
	

 	
 	

By:	
 	

/s/ Camille Samuels Pearson
 Camille Samuels Pearson

Managing Director

3000 Sand Hill Road

Building 4, Suite 210

Menlo Park, CA 94025
	
[SIGNATURE PAGE TO AMENDMENT NO. 1 TO

AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT]

	 	 	WINDAMERE II, LLC
	

 	
 	

By:	
 	

/s/ Scott Glenn
 Scott Glenn

Title: Managing Member

6402 Cardeno Drive

La Jolla, CA 92037
	

 	
 	
WINDAMERE III, LLC
	

 	
 	

By:	
 	

/s/ Scott Glenn
 Scott Glenn

Title: Managing Member

6402 Cardeno Drive

La Jolla, CA 92037
	

 	
 	

/s/ Eckard Weber
ECKARD WEBER, M.D.
	
[SIGNATURE PAGE TO AMENDMENT NO. 1 TO

AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT]

	 	 	The Board of Trustees of the Leland Stanford Junior University (SBST-LS)
	

 	
 	

By:	
 	

/s/ Martina Poquet
 Martina Poquet, Director—Separate Investments

Stanford Management Company

2770 Sand Hill Road

Menlo Park, CA 94025
	

 	
 	
GC&H INVESTMENTS, LLC
	

 	
 	

By:	
 	

/s/ John L. Cardoza
 John L. Cardoza

Managing Member

101 California Street, 5th Floor

San Francisco, California 94111-5800
	

 	
 	
VP COMPANY INVESTMENTS 2004, LLC
	

 	
 	

By:	
 	

/s/ Alan C. Mendelson

	 	 	Name:	 	Alan C. Mendelson

	 	 	Title:	 	Managing Member
 555 West Fifth Street, Suite 800

Los Angeles, California 90013
	

 	
 	
MENDELSON FAMILY TRUST
	

 	
 	

By:	
 	

/s/ Alan C. Mendelson
 Alan Mendelson

Trustee

76 De Bell Drive

Atherton, California 94027

[SIGNATURE PAGE TO AMENDMENT NO. 1 TO

AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT]

QuickLinks

Exhibit 4.8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00124-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00124-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00124-of-00352.parquet"}]]